Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lipidem + gemcitabine
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Lipidem + gemcitabine is a combination therapy consisting of Lipidem (a proprietary mixture of omega-3 polyunsaturated fatty acids—docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]) and the chemotherapeutic agent gemcitabine. This combination has demonstrated anti-proliferative and anti-invasive efficacy in vitro against pancreatic cancer cells and pancreatic stellate cells (PSCs), with PSCs showing the greatest sensitivity. The mechanism involves inhibition of cell proliferation, invasion, and platelet-derived growth factor (PDGF) secretion. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporation into DNA as its active triphosphate metabolite (dFdCTP), leading to masked chain termination and apoptosis in malignant cells[2][4][5]. Lipidem acts through modulation of cellular signaling pathways associated with inflammation, proliferation, and invasion.
- Other names
- docosahexaenoic acid and eicosapentaenoic acid combinationDHA/EPA combinationLipidem plus gemcitabine
02
Targets
DNA polymerase familyPDGFR (PDGFR family)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on lipidem + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lipidem + gemcitabine.